Table 1.

Dose-dependent increases in the apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1) and low-density lipoprotein (LDL)/high-density lipoprotein (HDL) ratios and dose-dependent decreases in HDL, ApoA1, and lipoprotein(a) (Lp[a]) concentrations at 0, 4, and 14 days after parenteral testosterone doses

Dose	500 mg			250 mg
Day	0	4	14	0	4	14
ApoB/ApoA1	0.49±0.03	0.47±0.03	0.61±0.03a	0.52±0.03	0.53±0.03	0.55±0.03
LDL/HDL	2.41±0.14	2.61±0.18b	2.86±0.19b	2.48±0.19	2.86±0.19b	2.62±0.17a
HDL, nmol/L	1.19±0.05	1.10±0.05b	1.08±0.04b	1.27±0.04	1.16±0.06b	1.12±0.05b
ApoA1, g/L	1.72±0.07	1.57±0.06a	1.41±0.05a	1.67±0.05	1.58±0.04	1.56±0.04c
Lp(a), mg/L
Median	96	100	68c	81	105	68
Range	50–589	50–542	50–472	50–603	50–623	50–567

Notes: “Day 0” refers to values before administration. Analysis of variance repeated-measures adjustment for multiple comparisons, Bonferroni corrected. Results are given as mean ± standard error of the mean except for those for Lp(a), which are given as median and range (Friedman test), as indicated.

^aP<0.0001;

^bP=0.001;

^cP<0.05. Data before and after administration of 125 mg of testosterone are not shown.